Industry dubs Pelosi’s drug pricing plan ‘extreme’
The Biotechnology Innovation Organization (BIO) has claimed that if the drug pricing plan unveiled by US House of Representatives Speaker Nancy Pelosi yesterday, September 19, becomes law, it will upend the US’s ability to lead the world in biomedical innovation.
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk
21 October 2019 The US House Committee on Energy & Commerce has voted to advance a drug pricing plan which would lower the cost of many prescription drugs.
1 August 2019 In a bid to lower drug prices for American patients, the Trump administration has proposed plans to allow the importation of cheaper drugs from Canada and other countries.